SOURCE-LINKED STUDY SUMMARY
The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
Full paper summarizedQuality not appraised
- What was studied
- A kidney-safety analysis reported kidney impairment, dehydration and low blood pressure. One retatrutide participant had serious acute kidney injury, possibly secondary to COVID-19.
- Who / model studied
- Exploratory analysis of two retatrutide trials included 281 participants with type 2 diabetes and 338 with overweight or obesity without diabetes, followed for 36 and 48 weeks. Both compared placebo; the diabetes trial also included dulaglutide.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- At the highest studied dose, urine albumin-to-creatinine ratio was 37.0% lower versus placebo in diabetes and 31.5% lower in obesity. Estimated kidney filtration was unchanged versus placebo in diabetes but increased in obesity. Absolute albumin reductions were modest.
- Limitations & context
- The analysis was exploratory, without adjustment for multiple comparisons. Few participants had existing kidney disease, follow-up was short, and no kidney outcome events occurred; prevention of kidney failure was not established.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.ekir.2025.03.049